Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: CMTM3 suppresses chordoma progress through EGFR/STAT3 regulated EMT and TP53 signaling pathway

Fig. 4

CMTM3 suppressed the EGFR/STAT3/EMT signaling pathway. A, B The expression of EMT-related markers and the phosphorylated and total EGFR, STAT3, AKT and ERK1/2 were analyzed in CMTM3 overexpressed chordoma cells by western blot. C, D Up, the transfection efficiency of the CMTM3 siRNAs was detected by western blot in MUG-Chor1 and U-CH1 cells, respectively (Scr: control siRNA, C-1#: CMTM3-1#, C-2#: CMTM3-2#). 100 μg of total protein lysates were loaded; Down, expression of EMT related markers: E-cadherin, N-cadherin and Vimentin, and the phosphorylated and total EGFR, STAT3, AKT and ERK1/2 were analyzed in CMTM3 silenced chordoma cells by western blot. Data were representative of three independent experiments. E, F The relative gray density of the indicated proteins shown in A, B, respectively (statistical analysis was carried out with CMTM3 vs. MOCK). C, D The relative gray density of the indicated proteins shown in C, D, respectively (statistical analysis was carried out with C-1# vs. Scr and C-2# vs. Scr). I Representative images are shown of IHC staining to assess the expression levels of EGFR, p-EGFR, p-STAT3, p-AKT and p-ERK1/2 in tumors from the mouse model of chordomas (*p < 0.05, **p < 0.01, ***p < 0.001). J Chordoma cells were treated with EGF (100 ng/mL) in the presence of CHX (25 μg /mL) for the indicated times and the cell lysates were subjected to immunoblotting with the indicated antibodies (MOI: 100)

Back to article page